Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Open-label, Phase I/II Study Investigating the Safety, Tolerability, and Preliminary Efficacy of 225Ac-SSO110 in Participants With Extensive Stage Small Cell Lung Cancer (ES-SCLC) or Merkel Cell Carcinoma (MCC) Receiving Standard of Care (SoC)

Next Previous
Trial Profile

A Multicentre, Open-label, Phase I/II Study Investigating the Safety, Tolerability, and Preliminary Efficacy of 225Ac-SSO110 in Participants With Extensive Stage Small Cell Lung Cancer (ES-SCLC) or Merkel Cell Carcinoma (MCC) Receiving Standard of Care (SoC)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Actinium-225-satoreotide-Ariceum-Therapeutics (Primary) ; Atezolizumab; Avelumab; Durvalumab; Pembrolizumab; Retifanlimab
  • Indications Merkel cell carcinoma; Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SANTANA-225
  • Sponsors Ariceum Therapeutics

Most Recent Events

  • 26 Aug 2025 According to an Ariceum Therapeutics media release, initiation of the study expected by 2H 2025. Expect to report initial safety data in early 2026 and preliminary efficacy findings in 2027.
  • 01 Aug 2025 Planned initiation date (estimated date of first participant enrollment) changed from 1 Jun 2025 to 1 Aug 2025.
  • 25 Jun 2025 Planned initiation date (estimated date of first participant enrollment) changed from 1 Apr 2025 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top